(38) showed that the oral intervention with Theracurmin® in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus could increase adiponectin expression, resulting in antiatherosclerotic action. This evidence concerns the gene ADIPOQ and type 1 diabetes mellitus.